[1]黄健,林天歆,李锴文,等.中国膀胱癌诊断和治疗现状调查及初步分析.中华泌尿外科杂志,2014,35:8-9. [2]鲍萍萍,彭鹏,顾凯,等.不同分子分型乳腺癌长期预后及治疗对预后的影响:上海乳腺癌生存研究.中华外科杂志,2015,53(12):928-934. [3]Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature, 2014,507(7492):315-322. [4]黄健,陈旭,林天歆.膀胱癌精准治疗现状与展望.中华泌尿外科杂志,2015,36(7):484-486. [5]Choi W, Porten S, Kim S, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell, 2014,25(2):152-165. [6]Masson-Lecomte A, Rava M, Real FX, et al. Inflammatory biomarkers and bladder cancer prognosis: a systematic review. Eur Urol, 2014,66(6):1078-1091. [7]王博,林建勋,于浩,等.CD8+T细胞的分布特征及其与膀胱癌预后关系的研究.中华泌尿外科杂志,2015,53(12):928-934. [8]Wang B, Wu S, Zeng H, et al. CD103+ tumor infiltrating lymphocytes predict a favorable prognosis in urothelial cell carcinoma of the bladder. J Urol, 2015,194(2):556-562. [9]Wang B, Liu H, Dong X, et al. High CD204+ tumor-infiltrating macrophage density predicts a poor prognosis in patients with urothelial cell carcinoma of the bladder. Oncotarget, 2015,6(24):20204-20214. [10]Margel D, Pevsner-Fischer M, Baniel J, et al. Stress proteins and cytokines are urinary biomarkers for diagnosis and staging of bladder cancer. Eur Urol, 2011,59(1):113-119. [11]Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol, 2001,19(3):666-675. [12]Smith SC, Baras AS, Dancik G, et al. A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol, 2011,12(2):137-143. [13]Kriegmair M, Baumgartner R, Knüchel R, et al. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J Urol, 1996,155(1):105-109. [14]Han J, Lin T, Xu K, et al. Improved detection of nonmuscle invasive urothelial carcinoma of the bladder using pirarubicin endoscopy: a prospective, single-center preliminary study. J Endourol, 2010,24(11):1801-1806. [15]Shen YJ, Zhu YP, Ye DW, et al. Narrow-band imaging flexible cystoscopy in the detection of primary non-muscle invasive bladder cancer: a "second look" matters?. Int Urol Nephrol, 2012,44(2):451-457. [16]陈光富,张旭,史立新,等.机器人辅助腹腔镜下根治性膀胱切除加尿流改道术的11备床分析.中华泌尿外科杂志,2012,33 (10):744-748. [17]Li K, Lin T, Fan X, et al.Systematic review and meta-analysis of comparative studies reporting early outcomes after robot-assisted radical cystectomy versus open radical cystectomy. Cancer Treat Rev, 2013,39(6):551-560. [18]Manny TB, Hemal AK.Fluorescence-enhanced robotic radical cystectomy using unconjugated indocyanine green for pelvic lymphangiography, tumor marking, and mesenteric angiography: the initial clinical experience. Urology, 2014,83(4):824-829. [19]Kamat AM, Porten S. Myths and mysteries surrounding bacillus Calmette-Guerin therapy for bladder cancer. Eur Urol, 2014,65(2):267-269. [20]Kamat AM, Briggman J, Urbauer DL, et al. Cytokine panel for response to intravesical therapy (CyPRIT): Nomogram of changes in urinary cytokine levels predicts patient response to Bacillus Calmette-Guerin. Eur Urol, 2016,69(2):197-200. [21]Zaid HB, Patel SG, Stimson CJ, et al. Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database. Urology, 2014,83(1):75-80. [22]Sakano S, Ogawa S, Yamamoto Y, et al. ERCC1 and XRCC1 expression predicts survival in bladder cancer patients receiving combined trimodality therapy. Mol Clin Oncol, 2013,1(3):403-410. [23]Li S, Wu J, Chen Y, et al. ERCC1 expression levels predict the outcome of platinum-based chemotherapies in advanced bladder cancer:a meta-analysis. Anticancer Drugs, 2014,25(1):106-114. [24]Van Allen EM, Mouw KW, Kim P, et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov, 2014,4(10):1140-1153. [25]Hoffmann AC, Wild P, Leicht C, et al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia, 2010,12(8):628-636. [26]Groenendijk FH, de Jong J, Fransen VDPE, et al. ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur Urol, 2016,69(3):384-388. [27]Font A, Taron M, Gago JL, et al. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Ann Oncol, 2011,22(1):139-144. [28]Baras AS, Gandhi N, Munari E, et al. Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma. Plos One, 2015,10(7):e131245. [29]Baras AS, Gandhi N, Munari E, et al. Identification and validation of protein biomarkers of response to neoadjuvant platinum chemotherapy in muscle invasive urothelial carcinoma. Plos One, 2015,10(7):e131245. [30]Carneiro BA, Meeks JJ, Kuzel TM, et al. Emerging therapeutic targets in bladder cancer. Cancer Treat Rev, 2015,41(2):170-178. [31]Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature, 2014,515(7528):558-562.
